Facet Joint Syndrome (FJS), also referred to as osteoarthritis, is a disabling pain at the joint between two vertebrae in one’s spine. It is a condition that affects millions of Americans every year, with symptoms that range from headaches, to difficulty moving the neck, to lower back pain. Currently, there is no long-term treatment for FJS, leaving patients vulnerable to recurring symptoms and ongoing follow-up appointments. Medovex Corp. ($MDVX), a developer of medical technology products, looks to remedy this issue through a patented technology that provides long-lasting pain relief.
Medovex recently announced the successful completion of a surgical innovation lab among leading European spine surgeons at NASS 2015. The lab featured a demonstration of the DenerveX™ System lead by Medovex’s executive team.
"The new DenerveX procedure will simplify the treatment for facet joint pain,” said Vik Kapoor M.D., a medical advisory member. “The device is easy to use, and has the potential to offer effective and longer term pain relief than standard radio frequency procedure. The intervention itself is a day case / office procedure."
A Promising Distribution Agreement
The positive reception of surgical innovation lab continues Medovex’s winning streak. Earlier this year, the company announced they would be entering into distribution agreements with Sydney-based Medical Innovators Pty. Ltd and Turkey based MEDS Medikal Ltd. Both agreements are for the distribution of the company’s DenerveX™ System.
“We are excited by the positive feedback received from the seventeen leading spine surgeons from the EU on the heels of our surgical innovation lab last week,” said Mr. Patrick Kullmann, President and COO of Mr. Patrick Kullmann, Medovex President and COO. “The purpose of the lab was to provide a training experience as part of our pre-European market launch activities by inviting members of our clinical advisory board and some of the leading European-based key opinion leaders."
Through Medovex’s successful demonstration of their innovative technology, their DenerveX system provides positive and promising momentum towards a minimally invasive treatment option. The reward is providing patients with long-term treatment and financial solutions.
"The feedback received from the recent demonstration is something we view as very important,” said Kullman. “The ability to gather insight from of the most preeminent spine surgeons in a close demonstration setting is invaluable as it allows for us to make certain specific refinements in advance of our future launch outside the US."
For more information about Medovex, visit www.medovex.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer